Impact of the completeness of revascularization and high bleeding risk status in acute coronary syndrome patients with multi-vessel disease: A retrospective analysis.

Objectives: To investigate the long-term mortality of acute coronary syndrome (ACS) patients with multivessel disease according to the level of completeness of revascularization (CR) and high-bleeding risk (HBR) status.

Design Setting And Participants: This retrospective study collected the data of ACS patients with multivessel disease who underwent percutaneous coronary intervention between May 2018 and February 2019. Complete to reasonable revascularization (CR) was defined by the residual Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score (RSS) of 0 to ≤8.

Coronary artery calcium (CAC) score for cardiovascular risk stratification in a Thai clinical cohort: A comparison of absolute scores and age-sex-specific percentiles.

Purposes: Coronary artery calcium (CAC) score provides a quantification of atherosclerotic plaque within the coronary arteries. This study aimed to examine the prevalence and CAC score distribution and to evaluate the association of each CAC score classifications with major adverse cardiovascular events (MACE) in a Thai clinical cohort.

Methods: This study was a retrospective observational cohort.

Circulating mitochondrial dysfunction as an early biomarker for contrast media-induced acute kidney injury in chronic kidney disease patients.

Contrast-induced acute kidney injury (CI-AKI) is the common hospitalized acute kidney injury (AKI). However, the diagnosis by serum creatinine might not be early enough. Currently, the roles of circulating mitochondria in CI-AKI are still unclear.

Clinical outcomes of an ultrathin-strut sirolimus-eluting stent in all-comers population: Thailand Orsiro registry.

Background: Despite numerous studies supporting the outperformance of ultrathin-strut bioresorbable polymer sirolimus-eluting stent (Orsiro SES, Biotronik AG), the generalizability of the study results remains unclear in the Asian population. We sought to evaluate the clinical outcomes of the Orsiro SES in unselected Thai population.

Methods: The Thailand Orsiro registry was a prospective, open-label clinical study evaluating all patients with obstructive coronary artery disease implanted with Orsiro SES.

GRACE score and cardiovascular outcomes prediction among the delayed coronary intervention after post-fibrinolytic STEMI patients in a limited PCI-capable hospital.

Background: In Thailand, due to limited availability of percutaneous coronary intervention (PCI)-capable hospitals, a number of patients with ST-elevation myocardial infarction (STEMI) after fibrinolytic therapy underwent the delayed coronary intervention (24 hours to 2 weeks). Existing tool such as the Global Registry of Acute Coronary Event (GRACE) to define patients at high risk of cardiovascular outcomes has been used widely, except for patients who had the delayed coronary intervention. We, therefore, evaluated the cardiovascular outcomes of STEMI patients who underwent the delayed coronary intervention.

ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand.

Background: The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab significantly reduces low-density lipoprotein cholesterol (LDL-C).

Objective: This study (ODYSSEY EAST) assessed the efficacy and safety of alirocumab vs ezetimibe in high cardiovascular risk patients from Asia.

Methods: Patients (n = 615) from China, India, and Thailand with hypercholesterolemia at high cardiovascular risk on maximally tolerated statin were randomized (2:1) to alirocumab (75 mg every 2 weeks [Q2W]; with dose increase to 150 mg Q2W at week 12 if week 8 LDL-C was >1.

Cardiovascular outcomes of early versus delayed coronary intervention in low to intermediate-risk patients with STEMI in Thailand: a randomised trial.

Background: The benefit of an early coronary intervention after streptokinase (SK) therapy in low to intermediate-risk patients with ST-elevation myocardial infarction (STEMI) still remains uncertain. The current study aimed to evaluate the cardiovascular outcomes of early versus delayed coronary intervention in low to intermediate-risk patients with STEMI after successful therapy with SK.

Methods: We randomly assigned low to intermediate Global Registry of Acute Coronary Events risk score to patients with STEMI who had successful treatment with full-dose SK at Lampang Hospital and Maharaj Nakorn Chiang Mai Hospital into early and delayed coronary intervention groups.

A clinical evaluation of the XIENCE V everolimus eluting stent in the treatment of patients with coronary artery disease: Result from Thailand Registry - XIENCE V performance evaluation (THRIVE study).

Objective: To evaluate the 2-year clinical outcomes of XIENCE V everolimus eluting stent (EES) for the treatment of coronary artery disease.

Background: Percutaneous coronary intervention with a drug eluting stent has become the preferred treatment in patients with coronary artery disease. Everolimus eluting stent had proven efficacy in randomized control trials but those trials may not represent daily practice of interventional cardiology.

The prognostic utility of GRACE risk score in predictive cardiovascular event rate in STEMI patients with successful fibrinolysis and delay intervention in non PCI-capable hospital: a retrospective cohort study.

Background: Fibrinolytic therapy is the main reperfusion therapy for most STEMI patients in several countries. Current practice guidelines recommended routine early pharmacoinvasive (within 3-24 h after successful fibrinolysis, however it cannot be performed in timely fashion due to limitation of PCI-capable hospitals. This study aimed to evaluate the prognostic utility of the GRACE score in patients receiving delayed intervention after successful fibrinolysis in non PCI-capable hospital.

Safety and tolerability of intradermal influenza vaccination in patients with cardiovascular disease.

Background: It is well-established that influenza vaccination reduces adverse cardiovascular outcomes in patients with cardiovascular diseases (CVD), however, the vaccine coverage rate in most countries remains low. The concern about the local adverse effects of intramuscular injection, particularly in CVD patients receiving antithrombotic therapy, is one of the important impediments. This study was conducted to assess the safety, side effects and tolerability of intradermal influenza vaccine in CVD patients.

Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome.

Aims: Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive.

Methods And Results: The study was a prospective randomized open with blinded endpoint (PROBE) study.

Plasma urocortin in acute myocardial infarction patients.

Background: Despite its proposed cardioprotective effect, the role of plasma urocortin in acute myocardial infarction (AMI) remains unknown. We investigated plasma profile of urocortin in AMI patients and evaluated its long-term prognostic performance.

Material And Methods: Sixty-six AMI patients and 21 healthy subjects were included in this study.

Complete right bundle branch block predicts mortality in Thai patients with chronic heart failure with reduced ejection fraction.

Background: Previous studies have shown that intraventricular conduction defect is associated with increased mortality in heart failure (HF) population. However, it is conflicting whether left bundle branch block (LBBB) or right bundle branch block (RBBB) is a better predictor for mortality.

Objective: To evaluate the relationship between patterns of bundle branch block (BBB) and all-cause mortality in Thai patients with chronic heart failure with reduced ejection fraction (HFrEF) and to compare the prognostic values of RBBB and LBBB in this population.

Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.

Background: Warfarin has been widely used for the prevention and treatment of thromboembolism. Warfarin therapy depends on interaction between physiological, environmental, and genetic factors. Vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) enzyme conjointly determine the warfarin maintenance dose.

Normal thoracic aortic diameter in Thai people by multidetector computed tomography.

Objective: To determine the normal size of the thoracic aorta among Thai people.

Material And Method: The aortic diameter of 73 Thai males and 56 Thai females, in four age groups, were measured from thoracic Multidetector Computed Tomography (MDCT) images. Aortic size were analyzed and correlated by age, sex, and vertebral body.

Evidence of influenza or influenza-like-illness preceding acute coronary syndrome.

This observational study determined the prevalence of influenza and influenza-like-illness (ILI) in patients hospitalized for acute coronary syndrome (ACS). Serological confirmation and a clinical history of influenza or a recent acute upper respiratory infection were obtained in 376 patients admitted to Maharaj Nakhon Chiang Mai Hospital, Thailand, from June 2006 through May 2007 for ACS. We found evidence of confirmed influenza preceding ACS in 47 patients (12.

In-hospital invasive strategy and outcomes in non-ST elevation acute coronary syndrome management from Thai Acute Coronary Syndrome Registry.

Background: The management guideline of acute coronary syndrome has been changed in recent years, especially in the group of non-ST elevation acute coronary syndrome (NSTE-ACS). Presently, there is no existing guideline in Thailand. Additionally, several different management factors of health care from Western countries being used.

Multi-link Vision and MiniVision stent registry in Asian patients with coronary artery disease: a prospective, multi-center study.

Background: Recent studies have showed that the fine mesh stents are associated with a significant reduction in both clinical and angiographic re-stenosis of the coronary arteries. To maintain a very satisfactory radio-opacity using the stents, Guidant of the USA has designed a new type of bare metal stents (BMS)-Multi-link (ML) Vision/ML MiniVision stents. The clinical outcomes of Asian patients with coronary artery disease (CAD) after implanting the Multi-link Vision or MiniVision stent were investigated in this study.

A predictive model for distinguishing ischemic from non-ischemic cardiomyopathy.

Objectives: To develop a predictive model to distinguish ischemic from non-ischemic cardiomyopathy

Material And Method: The authors randomly assigned 137 patients with LV systolic dysfunction into two subsets--one to derive a predictive model and the other to validate it. Clinical, electrocardiographic and echocardiographic data were interpreted by blinded investigators to the subsequent coronary angiogram results. Ischemic cardiomyopathy was diagnosed by the presence of significant coronary artery disease from the coronary angiogram.

Intracoronary brachytherapy: Initial Australasian experience with the Novoste Beta-Cath system.

Background: Coronary artery stenting is now performed in the vast majority of percutaneous interventional procedures worldwide. In-stent restenosis remains the major limitation of this technology and responds poorly to conventional interventional therapies. The only available treatment shown to impact upon this unfavourable response is endovascular radiation.